Gesynta Pharma AB

About Gesynta Pharma AB

Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1*, an important pro-inflammatory enzyme with a key role in endometriosis. Gesynta Pharma's research originated at Karolinska Institutet in Sweden. The company's leading compound, vipoglanstat, is a selective mPGES-1* inhibitor being developed as a new non-hormonal, non-opioid treatment with disease-modifying potential. Vipoglanstat is currently in Phase 2 clinical trials for endometriosis - a painful, chronic inflammatory disorder affecting about 10% of women of reproductive age. The condition often leads to a markedly reduced quality of life, particularly as many existing treatments fail to provide adequate symptom relief. Vipoglanstat has shown potent mPGES-1 inhibition and a favorable safety profile across Phase 1 and 2 clinical trials. Furthermore, a preclinical proof-of-concept study in an advanced model of endometriosis demonstrated that vipoglanstat significantly reduced pain-related behaviors and endometriotic lesions. A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase 1 for the treatment of chronic inflammatory pain. The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture, and other internationally renowned specialist investors. *mPGES-1: microsomal Prostaglandin E Synthase-1